statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) - Equities research analysts at HC Wainwright issued their Q2 2024 EPS estimates for shares of Acumen Pharmaceuticals in a note issued to...

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Expected to Earn Q2 2024 Earnings of ($0.26) Per Share

Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) and Inhibrx (NASDAQ:INBX - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two...

Acumen Pharmaceuticals (NASDAQ:ABOS) vs. Inhibrx (NASDAQ:INBX) Head-To-Head Analysis

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) saw a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 1,020,000 shares, an...

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Update

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS  Free Report)  Equities research analysts at HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for Acumen Pharmaceuticals...

HC Wainwright Weighs in on Acumen Pharmaceuticals, Inc.'s Q1 2024 Earnings (NASDAQ:ABOS)

Investors might want to bet on Acumen Pharmaceuticals, Inc. (ABOS), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates...

Acumen Pharmaceuticals (ABOS) Upgraded to Buy: What Does It Mean for the Stock?

Q4 2023 Acumen Pharmaceuticals Inc Earnings Call Transcript

Acumen Pharmaceuticals (NASDAQ:ABOS  Get Free Report)s stock had its buy rating restated by investment analysts at HC Wainwright in a research report issued to clients and...

Acumen Pharmaceuticals (NASDAQ:ABOS) Stock Rating Reaffirmed by HC Wainwright

Initiation of a Phase 2 study, ALTITUDE-AD, to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease expected in the first half of 2024 Initiation of a Phase 1 study to...

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights

Acumen Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation...

Acumen Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation

Acumen Pharmaceuticals's Earnings: A Preview

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft, and Caleb Finch in 1996 and is headquartered in Charlottesville, VA.

Watchers	1,097
52-Wk Low	$1.81
52-Wk High	$11.31

Volume	79,239.00
52-Wk High	$11.31
52-Wk Low	$1.81

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.28	--	--	N/A
Q1'24	-$0.26	-$0.25	4.19%	BEAT
Q4'23	-$0.32	-$0.28	11.89%	BEAT
Q3'23	-$0.26	-$0.24	8.64%	BEAT
Q2'23	-$0.35	-$0.28	19.14%	BEAT

ABOS Acumen Pharmaceuticals Inc

About

Feed

News

Earnings

Fundamentals